+44 20 8123 2220
info@marketpublishers.com

Ovarian Cancer: Update Bulletin [January 2018]

https://marketpublishers.com/r/O2F7BB47CF7EN.html
Date: December 2017
Pages: 0
Price: US$ 1,095.00 (Single User License)
ID: O2F7BB47CF7EN

Abstracts

This edition presents key opinion leader (KOL) views on recent developments in the ovarian cancer market. Topics covered include: US Food and Drug Administration (FDA) acceptance for Genentech's supplemental Biologics License Application (sBLA) for Avastin (bevacizumab) and chemotherapy, followed by Avastin alone, in the front-line setting; EU approval of Zejula (niraparib; Tesaro/Merck & Co.) for the treatment of recurrent ovarian cancer, irrespective of BRCA mutation or biomarker status; Clovis's supplemental New Drug Application (sNDA granted Priority Review in the US) for rucaparib (Rubraca) as a maintenance therapy for platinum-sensitive, recurrent ovarian cancer and for women showing a complete or partial response to platinum chemotherapy, with no requirement for diagnostic testing.

Business Questions:

What are KOL's current views on the amyloid theory of AD?

What are the KOLs' opinions on Avastin seeking approval in the front-line setting?

How is Avastin currently used and how is that going to change following approval as a front-line therapy?

Do the KOLs believe there any barriers to using Avastin as a front-line treatment?

What is the reaction from the experts following approval of Zejula, irrespective of BRCA mutation status?

Is Zejula likely to displace other PARP inhibitors already available on the market

+44 20 8123 2220
info@marketpublishers.com

for the treatment of ovarian cancer?

How do the KOLs view the adverse events reported from Phase III trials with Zejula?

Should Rubraca’s sNDA receive FDA approval, how likely is the drug to gain extensive market share ahead of its competitors?

What is the view of the experts on having three PARP inhibitors for the treatment of ovarian cancer?

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Ovarian Cancer: Update Bulletin [January 2018]
Product link: https://marketpublishers.com/r/O2F7BB47CF7EN.html
Price: US$ 1,095.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/O2F7BB47CF7EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970